Theravance Biopharma (TBPH)
(Delayed Data from NSDQ)
$11.52 USD
+0.31 (2.77%)
Updated Aug 8, 2025 04:00 PM ET
After-Market: $11.53 +0.01 (0.09%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth D Momentum C VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
TBPH 11.52 +0.31(2.77%)
Will TBPH be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for TBPH based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for TBPH
Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2
Zacks Industry Outlook Highlights Catalyst Pharmaceuticals, Zevra Therapeutics, Theravance Biopharma, Aldeyra Therapeutics and Larimar Therapeutics
TBPH: What are Zacks experts saying now?
Zacks Private Portfolio Services
5 Small Drug Stocks to Buy Amid Trump's New Tariff Threats
TBPH to Sell Remaining Trelegy Royalty Interest to GSK, Stock Rises
Theravance's Q1 Loss Wider Than Expected, Revenues Rise Y/Y
Other News for TBPH
Theravance Biopharma to Report Second Quarter 2025 Financial Results on August 12, 2025 | TBPH ...
Theravance Biopharma to Participate in an Upcoming Investor Conference | TBPH Stock News
Theravance Biopharma (TBPH) Target Price Raised to $25 By BTIG | TBPH Stock News
TBPH Stock Price Target Increased Following Milestone Payment | TBPH Stock News
Theravance Biopharma price target raised to $25 from $24 at BTIG